Safety and Efficacy of Sequential Therapy With Mexidol® in Patients With Chronic Cerebral Ischemia

PHASE3CompletedINTERVENTIONAL
Enrollment

318

Participants

Timeline

Start Date

November 5, 2019

Primary Completion Date

December 8, 2020

Study Completion Date

December 8, 2020

Conditions
Chronic Cerebral Ischemia
Interventions
DRUG

Mexidol

50 mg/ml IV solution, 250 mg tablets

DRUG

Placebo

Placebo IV solution, Placebo tablets

Trial Locations (14)

100187

"Centre for Neurology and Neurorehabilitation n.a. N. M. Madzhido, OOO Neyromed Servis", Tashkent

125367

"Federal State Budget Research Institution Research Center of Neurology", Moscow

125445

"Federal State Budget Educational Institution of Further Professional Education Russian Medical Academy of Continuous Professional Education", Moscow

150000

"OOO Centre for Evidence-Based Medicine", Yaroslavl

150030

"State Budget Healthcare Institution of the Yaroslavl Region Clinical Hospital No.2", Yaroslavl

152040

"Regional Budget Healthcare Institution Ivanovo Regional Clinical Hospital", Ivanovo

194044

"Federal State Budget Military Educational Institution of Higher Education Military Medical Academy n.a. S.M.Kirov", Saint Petersburg

197706

City Hospital No.40 of the Kurortny District, Sestroretsk

394024

"Private Healthcare Institution Clinical Hospital RR-Medicine of Voronezh", Voronezh

420012

"Federal State Budget Educational Institution of Higher Education Kazan State Medical University", Kazan'

454092

"Municipal Autonomous Healthcare Insitution of the Order of the Red Banner of Labour City Clinical Hospital No.1", Chelyabinsk

620102

"State Budget Healthcare Institution of the Sverdlovsk Region Sverdlovsk Regional Clinical Hospital No.1", Yekaterinburg

630054

"State Budget Healthcare Institution of the Novosibirsk Region City Hospital № 34", Novosibirsk

630117

"Federal State Budget Research Institution Federal Research Center for Fundamental and Translational Medicine", Novosibirsk

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pharmasoft

INDUSTRY